The Schedule III Shift: Cannabis Regulation, Research, and Risk
July 27, 2026 | 12:00PM–1:30PM ET | Live Webinar
Overview
The evolving federal cannabis rescheduling framework could reshape medical research, regulatory compliance, reimbursement pathways, and product liability exposure across the industry. In this webinar, panelists will unpack key insights emerging from the DEA hearings and discuss what Schedule III status may mean in practice—from DEA oversight and FDA-approved pathways to state-licensed markets and Medicare reimbursement implications. The discussion will also examine evolving compliance obligations, litigation risks, warning-label requirements, and the potential impact of federal changes on existing state cannabis programs and the broader regulated market. You’ll leave with practical strategies to help your organization prepare for regulatory change, manage risk, and respond effectively to emerging developments in the evolving cannabis landscape.
Speakers

Ziva Cooper
Read Bio
Research Director, Cannabis Research Initiative, UCLA

Melis Coraggio
Read Bio
Consultant, King & Spalding LLP

Rosalie Liccardo Pacula
Read Bio
Professor of Health Policy, Economics and Law, USC Sol Price School of Public Policy

Howard Sklamberg
Read Bio
Partner, Arnold & Porter LLP
FDLI applies for CLE credits in Ohio and Virginia. These CLE approvals also may be honored by other states. The CLE credits will be posted as they are granted and registrants can request to be notified when approval is received.


